| Gout prevalence |
This measure details the prevalence of identified gout in those enrolled with primary health organisations. Rates of gout are particularly high in Māori and Pacific males, meaning districts with a high Māori and/or Pacific population have higher prevalence. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), Primary Health Organisation Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Dispensed prednisone, colchicine or a non-steroidal anti-inflammatory drug without urate-lowering therapy |
This measure shows the percentage of people with identified gout who were dispensed any of colchicine, prednisone or funded non-steroidal anti-inflammatory drugs (NSAIDs), but not dispensed urate-lowering therapy in a year. Acute gout flares are treated with colchicine, oral corticosteroids such as prednisone or NSAIDs. This measure may reflect people experiencing acute gout flares who are not on long-term preventive therapy for gout. Gout management guidelines state that people experiencing frequent (two or more) acute gout flares per year should be offered long-term urate-lowering therapy. Although NSAIDs are effective at treating acute gout flares, these medicines have considerable side effects including kidney injury and peptic ulcer disease. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Dispensed prednisone, colchicine or a non-steroidal anti-inflammatory drug |
This measure shows the percentage of people with identified gout who were dispensed any of colchicine, prednisone or funded non-steroidal anti-inflammatory drugs (NSAIDs) in a year. Acute gout flares are treated with colchicine, oral corticosteroids such as prednisone or NSAIDs. Gout management guidelines state that people experiencing frequent (two or more) acute gout flares per year should be offered long-term urate-lowering therapy. Although NSAIDs are effective at treating acute gout flares, these medicines have considerable side effects including kidney injury and peptic ulcer disease. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Dispensed a non-steroidal anti-inflammatory drug without urate-lowering therapy |
This measure shows the percentage of people with identified gout who were dispensed funded non-steroidal anti-inflammatory drugs (NSAIDs) but not dispensed urate-lowering therapy. While it is not known whether it was gout that led to an NSAID being dispensed, high rates of NSAID dispensing without urate-lowering therapy use may reflect people using NSAIDs to manage their acute gout flares. International best practice indicates that people experiencing frequent gout flares (two or more per year) should be offered long-term urate-lowering therapy. Large variation may reflect patient preference and/or variable clinical practice. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Hospital admissions in the general population |
This measure shows the rate of hospital admissions with a primary diagnosis of gout in the general population per 100,000. Variation in admission rates due to gout may indicate different admission criteria between districts , poor gout control or limited access to primary care. |
National Minimum Dataset (NMDS), Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Hospital admissions for people with gout |
This measure shows the rate of hospital admissions with a primary diagnosis of gout in those identified with gout per 100,000. Variation in admission rates due to gout may indicate different admission criteria between districts , poor gout control or limited access to primary care. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), Primary Health Organisation (PHO) Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Dispensed a non-steroidal anti-inflammatory drug |
This measure shows the percentage of people with identified gout who were dispensed funded non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are often the first line of treatment for acute gout flares and some can be purchased from a pharmacy without a prescription. Although NSAIDs are effective at treating acute gout flares, these medicines have considerable side effects including kidney injury and peptic ulcer disease. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| People dispensed an antibiotic specifically indicated for urinary tract infections, rate per 100 |
This measure details the rate per 100 of people dispensed an antibiotic specifically indicated for urinary tract infections (UTIs). Nitrofurantoin or trimethoprim are recommended as first-line treatment for UTIs. Norfloxacin is second-line treatment. The rationale for this measure is to explore the use of antibiotics for UTIs, with a view to identifying whether there are areas of high use of these antibiotics. |
Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Ministry of Health |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| People in ARC dispensed an antibiotic specifically indicated for UTIs, rate per 100 |
This measure details the rate per 100 of people listed in ARC dispensed an antibiotic specifically indicated for urinary tract infections (UTIs). Nitrofurantoin or trimethoprim are recommended as first-line treatment for UTIs. Norfloxacin is second-line treatment. The rationale for this measure is to explore the use of antibiotics for UTIs, with a view identifying whether there are areas of high use of these antibiotics. |
Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Ministry of Health |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Surgical hospital admissions with an antibiotic dispensed within 30 days of discharge, rate per 100 |
This measure details the rate per 100 of surgical hospital admission with an antibiotic dispensed within 30 days of discharge. It is recommended that, along with good infection control, antibiotics be prescribed only when needed, with the narrowest spectrum of antimicrobial activity. It is not best practice for antibiotics to be administered routinely postoperatively. The National Institute for Health and Care Excellence recommends antibiotics be used only in cases where infection is clinically evident. Previous research in Aotearoa New Zealand concluded a significant proportion of antibiotics dispensed in patients discharged following surgery was inappropriate and recommended enhanced antimicrobial stewardship in this area. |
Pharmaceutical Collection (PHARMS), National Minimum Dataset (NMDS), Ministry of Health |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
